SCHEMBL4465196

SCHEMBL4465196

COC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.74

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CTSS P25774 13/20 0.74
CTSK P43235 11/20 0.74
CTSB P07858 4/20 0.74
CTSL P07711 2/20 0.74
AKT1 P31749 1/20 0.64
ACE P12821 1/20 0.58
REN P00797 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465200 1.00 CTSS (0.74) CTSSCTSKCTSBCTSLAKT1
SCHEMBL10767107 0.98 CTSS (0.71) CTSSCTSKCTSBCTSLAKT1
SCHEMBL2793925 0.91 CTSS (0.76) CTSSCTSKCTSBCTSLAKT1
SCHEMBL1001781 0.91 CTSS (0.76) CTSSCTSKCTSBCTSLAKT1
SCHEMBL12706400 0.90 BCL2 (0.65) CTSSCTSKCTSBCTSLAKT1
SCHEMBL12826514 0.90 CTSS (0.74) CTSSCTSKCTSBCTSLAKT1
SCHEMBL30279290 0.90 REN (0.63) CTSSCTSKCTSBCTSLAKT1
SCHEMBL28916808 0.90 REN (0.63) CTSSCTSKCTSBCTSLAKT1
SCHEMBL18154315 0.89 CTSS (0.69) CTSSCTSKCTSBCTSLAKT1
SCHEMBL10456411 0.89 CTSS (0.69) CTSSCTSKCTSBCTSLAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176852-A Preparation method of amino acid with protection tetrapeptide 四川鸿日医药科技有限公司 2024-12-24 CN claimed
US-20250136563-A1 THIADIAZOLONE DERIVATIVES USEFUL AS AMPK ACTIVATOR BETAGENON AB (SE) 2025-05-01 US disclosed
CN-119176852-A Preparation method of amino acid with protection tetrapeptide 四川鸿日医药科技有限公司 2024-12-24 CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
EP-4396171-A1 THIADIAZOLONE DERIVATIVES USEFUL AS AMPK ACTIVATOR Betagenon AB (SE) 2024-07-10 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
WO-2023031609-A1 THIADIAZOLONE DERIVATIVES USEFUL AS AMPK ACTIVATOR BETAGENON BIO AB (SE) 2023-03-09 WO disclosed
US-20230046194-A1 Ribosome-Mediated Incorporation of Peptides and Peptidomimetics ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-02-16 US disclosed
US-20190144924-A1 BIOSENSORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2019-05-16 US disclosed
WO-2016118877-A1 RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2016-07-28 WO disclosed
US-9243028-B2 Facile amide formation via S-nitroso thioacid intermediates WASHINGTON STATE UNIVERSITY (US) 2016-01-26 US disclosed
US-20120190820-A1 FACILE AMIDE FORMATION VIA S-NITROSO THIOACID INTERMEDIATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-07-26 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed
EP-0217804-B1 ANALOGS OF SUBSTANCES P ENICHEM S.p.A. (IT) 1991-10-02 EP disclosed
EP-0217804-A1 ANALOGS OF SUBSTANCES P. ENICHEM SPA (IT) 1987-04-15 EP disclosed
EP-0075895-A2 Pharmaceutical amides, and preparation, formulations and use thereof THE WELLCOME FOUNDATION LIMITED (GB) 1983-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046194-A1 Ribosome-Mediated Incorporation of Peptides and Peptidomimetics NPEPPS, DNPEP, AARS1 CTSS 2862/4885CTSK 2200/4885CTSB 2609/4885
US-20250136563-A1 THIADIAZOLONE DERIVATIVES USEFUL AS AMPK ACTIVATOR PRKAB1, PRKAG1, PRKAA1 CTSS 4104/4885CTSK 2422/4885CTSB 4105/4885
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CTSS 3436/4885CTSK 3609/4885CTSB 2896/4885
US-20120190820-A1 FACILE AMIDE FORMATION VIA S-NITROSO THIOACID INTERMEDIATES NAAA, TST, ASNS CTSS 3240/4885CTSK 2813/4885CTSB 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.